Papillomavirus oncoproteins as vaccine candidates.
Galloway
D A
DA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D009856:Oncogene Proteins, Viral; D027383:Papillomaviridae; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014616:Vaccinia virus / Q000235:genetics*
D004268:DNA-Binding Proteins; C068651:E6 protein, Human papillomavirus type 16; C052603:E6 protein, Human papillomavirus type 18; C052633:E7 protein, Human papillomavirus type 18; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D014614:Vaccines, Synthetic; C059731:oncogene protein E7, Human papillomavirus type 16